Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models

OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus. Collaborators also reported that S/F-iTregs generated from samples obtained from patients with Pemphigus also showed potent inhibition of autologous T cell proliferation in vitro.

Pemphigus is a serious and sometimes fatal autoimmune skin disease. RegCell's proprietary platform allows for creating induced antigen-specific regulatory T-cells (Tregs) that are stable in vivo and maintain a high degree of functionality (S/F-iTregs). RegCell was cofounded by Professor Shimon Sakaguchi from Osaka university and Kyoto university, who is credited with the original discovery of Tregs.

Tregs play a central role in managing immune self-tolerance and depleted or dysfunctional Tregs are characteristic of many autoimmune disorders. "There has been interest in using Tregs as a treatment for autoimmune disorders for many years.  However, to date, these efforts have been limited by lack of antigen-specificity and persistence. The ability to create stable/functional Treg cells that are antigen-specific has until now been elusive. We believe that RegCell's proprietary platform can accomplish this goal by inducing Tregs from antigen-specific effector T-cells that appear to maintain their functionality, and we look forward to advancing our S/F-iTreg platform into clinical development", said Professor Sakaguchi.

About RegCell

RegCell is a preclinical-stage biotechnology company located in Japan with investment from leading Japanese institutional investors including The University of Tokyo Edge Capital Partners.  RegCell is developing S/F-iTregs as a potential treatment for patients with autoimmune disorders and to prevent transplant rejection. 

For more information about RegCell please visit https://regcell.jp/en/

Contact: Daisuke Ishikawa, Ph.D. (hpregcell@regcell.jp)

SOURCE RegCell Co., Ltd.

These press releases may also interest you

at 10:10
In a remarkable display of innovation and dedication to audio excellence, IPRO, renowned for protecting electronics from water damage without compromising sound quality, has raised the bar with an innovative new waterproof acoustic solution that has...

at 09:50
PCS, a leading provider of 24/7 outsourced technology services and IT helpdesk support, is thrilled to announce the opening of its new office in Florida. Located in Sarasota, this expansion solidifies PCS's growing national footprint across the...

at 09:00
With the return of cold weather, EcoFlow, a portable power and eco-friendly energy solutions company, is offering its biggest discounts ever on its best-selling portable power stations for Amazon's Prime Big Deals Day sales event. Customers can save...

at 08:30
Integrated Oncology Network (ION) is implementing Fuse Oncology's (Fuse) groundbreaking product, S!GNAL, across its extensive network, following a highly successful trial that demonstrated the quantifiable value of the software. ION's S!GNAL trial...

at 07:51
iFOREX has recently opened a new office in Dubai, to continue their global expansion as a market leader. "We are happy to announce that we are opening an office in Dubai," says the head of the new office. "This will help iFOREX engage with our...

at 07:10
Government software provider Mitchell Humphrey & Co. is proud to join the line-up of exhibitors at the International Code Council (ICC) Annual Conference & Expo beginning October 8. The team will be showcasing their cloud-based FastTrackGov® (FTG)...

News published on and distributed by: